A Rutgers University study found that GLP-1 medications like Ozempic and Wegovy may reduce violent behavior risk by weakening the link between impulsivity, alcohol use, and violence. The study analyzed data from 7,521 U.S. adults, focusing on 821 GLP-1 users, and suggested these drugs might act similarly to cognitive behavioral therapy. Researchers caution the findings are not causal and call for more research on GLP-1s' impact on behavior and public safety. These drugs, originally for diabetes and obesity, are increasingly used and linked to other health benefits and side effects.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
